OR WAIT null SECS
May 18, 2023
Waters Corporation expected to boost growth in bioanalytical characterization for new modalities with acquisition of Wyatt Technology.
May 16, 2023
In a brief, the Federal Trade Commission cited concerns about the acquisition resulting in an increased monopoly on Amgen’s newly acquired thyroid eye disease and chronic refractory gout treatments.
May 10, 2023
Private investors from Advent International and Warburg Pincus will operate the assets as an independent CDMO.
April 18, 2023
Merck will acquire Prometheus Biosciences, a clinical-stage biotechnology company specializing in immune-mediated diseases, at a total equity valuation of $10.8 billion.
April 05, 2023
Sartorius’ acquisition of Polyplus is designed to strengthen its cell and gene therapy capabilities.
March 30, 2023
The Supreme Court heard oral arguments concerning the legitimacy of “genus clauses” in bio/pharma patents.
March 29, 2023
Narcan, from Emergent Solutions, will be the first naloxone product permitted for use without prescription by FDA.
March 16, 2023
Pfizer will acquire all outstanding shares of Seagen for a total of $43 billion.
March 14, 2023
Sumitovant Bipharma has completed its acquisition of Myovant Sciences for approximately $1.7 billion.
March 13, 2023
Silicon Valley Bank has collapsed, leaving many biotechnology companies unsure of the future.